Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4182 - Clinical and Immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam.

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Immunotherapy

Presenters

Juan Marquez-Manriquez

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

J.P. Marquez-Manriquez1, J.A.M. Briseno2, K. Quayle3, L.M. Fernandez3, I.R. Barajas3, G. Torres-Montano3, F.A. Durazo-Bustamante4, A. Durazo-Acuna4, L. Rangel-Reyna3, D. Lopez-Hernandez3, A. Rodriguez-Jasso2, M. Trujillo-Acosta3, E. Ramos-Garcia4, S. Icedo-Zamora4, P.A.L. Diaz4

Author affiliations

  • 1 Immunoncology Clinical Reserach, Centro de Investigacion de Cancer en Sonora campus Seattle (CICS USA), 98103 - Seattle/US
  • 2 Immunooncopathology, Centro de Investigacion de Cancer en Sonora campus Ciudad Obregon, Sonora, Mexico, 85000 - Ciudad Obregon/MX
  • 3 Immunooncology Clinical Reserach, Centro de Investigacion de Cancer en Sonora campus Seattle (CICS USA), 98103 - Seattle/US
  • 4 Clinical Oncology And Immunooncology, Centro de Investigacion de Cancer en Sonora campus Ciudad Obregon, Sonora, Mexico, 85000 - Ciudad Obregon/MX
More

Resources

Abstract 4182

Background

Several patients progressed with their cancer disease despite treatment and eventually they become refractory. We selected patients from several malignancies with PD despite standard of care treatment (n = 30) and performed a pilot clinical study to evaluate the effect of two intravenously, two oral and one subcutaneously agent. With this in mind and with a systematic review and immunomodulatory, anti-angiogenic and anti-tumoral validation of each drug was studied. We tested the preexisting CD8 and Th1 antigen specific immune response against several clinically relevant peptides from bad prognosis proteins.

Methods

30 subjects were included after the CICS ethics committee approved the protocol. The inclusion criteria include ECOG=0, complete CT scan from neck, thorax, abdomen and pelvis, laboratory tests such as CBC, phase acute proteins, etc. The patients were accepted after initial IFN-gamma and Elispot assays were done to make sure we have only patients with Th1 and CD8 immune response, as we know that ipilimumab unleashes every T cell. The tumors included were PDAC (n = 5), HGSOC (n = 12), TNBC (n = 10) and MM (3). The patients received the oral and the IV treatment biweekly for 4 months.

Results

We had 60% of CR and 40% of PR. The tumor with more significant response was ovarian (90%). There was an immunological correlation of CD8 immune response between in both CR (p = 0.001) and PR (p = 0.05). The combination was well tolerated and after 16 months of stopping the treatment some patients have persistent CD8 antigen specific immune response.

Conclusions

The combination is clinically feasible, looks promising and we now understand the importance of preserving the immune response and the use of biomarkers to improve the rational and generate new combinations with this approach to improve clinical outcomes.

Clinical trial identification

DOES NOT APPLY

Legal entity responsible for the study

CENTRO DE INVESTIGACION DE CANCER EN SONORA CAMPUS CIUDAD OBREGON, SONORA, MEXICO

Funding

Fundacion del centro de investigacion de cancer en sonora (cics) campus ciudad obregon, sonora, Mexico.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.